Pfizer fesoterodine "approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer's overactive bladder treatment fesoterodine is "approvable," according to Pfizer, which told Pharmaceutical Approvals Monthly that it received the letter during the week of Jan. 22. Pfizer acquired the agent from Schwarz in April (1Pharmaceutical Approvals Monthly May 2006, p. 26). Pfizer's market-leading urinary incontinence therapy Detrol LA (tolterodine) has been competing in an increasingly crowded market, and faces patent expiry in 2012...
You may also be interested in...
Licensing In Brief
Pfizer gains Schwarz urology agent fesoterodine: Pfizer has an estimated user fee date in January 2007 for incontinence therapy fesoterodine, acquired from Schwarz under a deal announced April 13. Schwarz' fesoterodine NDA, submitted in March for treatment of overactive bladder, is receiving a standard 10-month review at FDA. The firm also submitted an EU marketing authorization application in March. Under the terms of the licensing deal, Pfizer will make a $100 mil. up-front payment to Schwarz, up to $110 mil. in milestone payments, plus royalties on sales of the anti-muscarinic agent. Schwarz also will collect royalties on sales of Pfizer's established incontinence treatment Detrol (tolterodine), approved in 1998; the deal ends a patent dispute between Pfizer and Schwarz over fesoterodine. The NDA includes Phase III data comparing fesoterodine to placebo and to tolterodine. The study showed statistically significant improvement compared to placebo in the primary endpoints of change in micturition frequency, change in number of urge incontinence episodes and self-assessed treatment response. Schwarz notes that "improvements with the active comparator were below those achieved with fesoterodine"...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.